Archive · 2 Sep 2026
Weekly HIV Pill Matches Daily Treatment in Phase 3 Trial
A new HIV pill that is taken once a week was tested in a large clinical trial.
In this study, it worked about as well as medicine taken every day.
The people in the study already had very low levels of HIV.
They had been taking treatment for at least six months.
None had previously experienced treatment failure.
This means the trial mostly looked at people changing from one successful treatment to another.
Experts say the results are encouraging but do not show that the weekly pill will work equally well for everyone with HIV.
More information is needed to understand how it performs in different groups of people.
A once-weekly HIV pill showed results comparable to daily treatment in a Phase 3 trial.
Experts said the findings do not prove the pill will work equally well for everyone with HIV.
The trial mainly studied people switching from existing HIV treatment.
Participants had already achieved suppressed HIV levels before joining the trial.
All participants had received treatment for at least six months and had no history of treatment failure.
- Who
- People living with HIV who were already receiving successful treatment, along with experts interpreting the results.
- What
- A Phase 3 trial found that a once-weekly HIV pill matched daily treatment in the study.
- When
- During a Phase 3 clinical trial; no specific date was provided.
- Where
- Not specified in the article.
- Why
- To assess how the once-weekly pill compared with daily HIV treatment, primarily among people switching therapies.
Encouraging Trial Results
Limits and Expert Caution
How broadly the findings apply
Encouraging Trial Results
The once-weekly pill matched daily treatment in a Phase 3 trial, suggesting it may be a promising alternative for some patients.
Limits and Expert Caution
Experts caution that the trial mainly involved people whose HIV was already suppressed, who had been treated for at least six months, and who had no history of treatment failure; therefore, the results may not apply equally to everyone living with HIV.
- Treatment frequency
- The new pill is taken once weekly.
- Comparison
- The weekly pill matched daily treatment in the Phase 3 trial.
- Trial design
- The trial was primarily a switch study.
- Participants' HIV status
- Participants already had suppressed HIV.
- Prior treatment
- Participants had received treatment for at least six months.
- Treatment history
- Participants had no history of treatment failure.
- Expert caution
- The findings should not be interpreted as proof that the weekly pill will work equally well for everyone living with HIV.